Steven Radowitz M.D.

Steven Radowitz, M.D., started his career in New York during the peak of the opioid and AIDS crises. Dr. Radowitz has a wealth of experience seeing the effects trauma and addiction can have on our physical health. Dr. Radowitz joined Nushama, at the intersection of science and spirituality, to oversee and develop treatment modalities. He believes psychedelic medicine’s framework of neuroscience, mystical experience, and integration therapy is the future of mental wellness, and current solutions often fall short, treating symptoms without addressing underlying issues. He and the Nushama team have administered more than 10,000 ketamine journeys for mood disorders. In addition to Nushama’s ketamine-assisted therapy protocol for mood disorders, he leads Ketamine for the Reduction of Alcohol Relapse (KARE), an innovative protocol that studies have shown to be 86 percent effective after six months.

Dr. Radowitz was formerly medical director of the inpatient alcohol and opiate detox and treatment unit at St. Vincent’s NYC Midtown medical center. Practicing internal medicine since 1998, he also formerly ran the primary care program at a number of top-tier investment banks and maintained a private practice specializing in general medicine, HIV care, and preventive medicine. Overall, he saw the connection between chronic stress and health and wanted to make a difference, leading to his career transition to psychedelic medicine.

He has been a DEA-licensed provider for buprenorphine maintenance treatment for opiate dependence for over a decade. He recently co-authored the largest IV ketamine for PTSD study to date—available as a preprint and pending peer review. The landmark findings make the case for a psychedelic therapy paradigm, as 75 percent of participants gained clinically meaningful improvement and 61 percent experienced remission of symptoms.